Literature DB >> 22042430

Next-generation sequencing reveals regional differences of the α-synuclein methylation state independent of Lewy body disease.

L de Boni1, S Tierling, S Roeber, J Walter, A Giese, Hans A Kretzschmar.   

Abstract

The α-synuclein gene (SNCA) plays a major role in the aetiology of Lewy body disease (LBD) including Parkinson's disease (PD). Point mutations and genetic alterations causing elevated gene expression are causally linked to familial PD. To what extent epigenetic changes play a role in the regulation of α-synuclein expression and may contribute to the aetiology of sporadic LBD is a matter of debate. We analysed the methylation state of the promoter region and a CpG-rich region of intron 1 of α-synuclein in several brain regions in sporadic LBD and controls using 454 GS-FLX-based high-resolution bisulphite sequencing. Our results indicate that there are significant differences in the level of methylation between different brain areas. The overall methylation levels in the promoter and intron 1 of α-synuclein are rather low in controls and-in contrast to previously reported findings-are not significantly different from LBD. However, single CpG analysis revealed significant hyper- and hypomethylation at different positions in various brain regions and LBD stages. A slight overall increase in methylation related to LBD patients' age was detected.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22042430     DOI: 10.1007/s12017-011-8163-9

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  46 in total

Review 1.  Epigenetics in neurodegeneration: a new layer of complexity.

Authors:  Sueli C F Marques; Catarina R Oliveira; Claudia M F Pereira; Tiago F Outeiro
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-08-22       Impact factor: 5.067

Review 2.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

Review 3.  Epigenetic regulation of gene expression in physiological and pathological brain processes.

Authors:  Johannes Gräff; Dohoon Kim; Matthew M Dobbin; Li-Huei Tsai
Journal:  Physiol Rev       Date:  2011-04       Impact factor: 37.312

4.  Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein.

Authors:  L Zhu; S van den Heuvel; K Helin; A Fattaey; M Ewen; D Livingston; N Dyson; E Harlow
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

5.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.

Authors:  Eirene Kontopoulos; Jeffrey D Parvin; Mel B Feany
Journal:  Hum Mol Genet       Date:  2006-09-07       Impact factor: 6.150

6.  α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity.

Authors:  Huajun Jin; Arthi Kanthasamy; Anamitra Ghosh; Yongjie Yang; Vellareddy Anantharam; Anumantha G Kanthasamy
Journal:  J Neurosci       Date:  2011-02-09       Impact factor: 6.167

7.  Genome-wide divergence of DNA methylation marks in cerebral and cerebellar cortices.

Authors:  Yurong Xin; Benjamin Chanrion; Meng-Min Liu; Hanga Galfalvy; Ramiro Costa; Boro Ilievski; Gorazd Rosoklija; Victoria Arango; Andrew J Dwork; J John Mann; Benjamin Tycko; Fatemeh Haghighi
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

8.  The tumor suppressor gene hypermethylated in cancer 1 is transcriptionally regulated by E2F1.

Authors:  Mathias Jenal; Emmanuelle Trinh; Christian Britschgi; Adrian Britschgi; Vincent Roh; Stephan A Vorburger; Andreas Tobler; Dominique Leprince; Martin F Fey; Kristian Helin; Mario P Tschan
Journal:  Mol Cancer Res       Date:  2009-06-02       Impact factor: 5.852

9.  BiQ Analyzer HT: locus-specific analysis of DNA methylation by high-throughput bisulfite sequencing.

Authors:  Pavlo Lutsik; Lars Feuerbach; Julia Arand; Thomas Lengauer; Jörn Walter; Christoph Bock
Journal:  Nucleic Acids Res       Date:  2011-05-11       Impact factor: 16.971

10.  Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells.

Authors:  Madeleine P Ball; Jin Billy Li; Yuan Gao; Je-Hyuk Lee; Emily M LeProust; In-Hyun Park; Bin Xie; George Q Daley; George M Church
Journal:  Nat Biotechnol       Date:  2009-03-29       Impact factor: 54.908

View more
  22 in total

Review 1.  Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.

Authors:  Subhrangshu Guhathakurta; Eugene Bok; Baggio A Evangelista; Yoon-Seong Kim
Journal:  Prog Neurobiol       Date:  2017-04-23       Impact factor: 11.685

Review 2.  CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.

Authors:  Fatemeh Safari; Gholamreza Hatam; Abbas Behzad Behbahani; Vahid Rezaei; Mazyar Barekati-Mowahed; Peyman Petramfar; Farzaneh Khademi
Journal:  Cell Mol Neurobiol       Date:  2019-11-26       Impact factor: 5.046

3.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

Review 4.  Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalities.

Authors:  Navneet Ammal Kaidery; Shaista Tarannum; Bobby Thomas
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

5.  Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients.

Authors:  Rubén Fernández-Santiago; Iria Carballo-Carbajal; Giancarlo Castellano; Roger Torrent; Yvonne Richaud; Adriana Sánchez-Danés; Roser Vilarrasa-Blasi; Alex Sánchez-Pla; José Luis Mosquera; Jordi Soriano; José López-Barneo; Josep M Canals; Jordi Alberch; Ángel Raya; Miquel Vila; Antonella Consiglio; José I Martín-Subero; Mario Ezquerra; Eduardo Tolosa
Journal:  EMBO Mol Med       Date:  2015-12       Impact factor: 12.137

6.  Hypomethylation of intron1 of α-synuclein gene does not correlate with Parkinson's disease.

Authors:  Subhrangshu Guhathakurta; Baggio A Evangelista; Susmita Ghosh; Sambuddha Basu; Yoon-Seong Kim
Journal:  Mol Brain       Date:  2017-02-07       Impact factor: 4.041

7.  DNA methylation alterations in iPSC- and hESC-derived neurons: potential implications for neurological disease modeling.

Authors:  Laura de Boni; Gilles Gasparoni; Carolin Haubenreich; Sascha Tierling; Ina Schmitt; Michael Peitz; Philipp Koch; Jörn Walter; Ullrich Wüllner; Oliver Brüstle
Journal:  Clin Epigenetics       Date:  2018-01-29       Impact factor: 6.551

8.  miRNAs and their putative roles in the development and progression of Parkinson's disease.

Authors:  Garry Wong; Richard Nass
Journal:  Front Genet       Date:  2013-01-09       Impact factor: 4.599

Review 9.  DNA methylation, a hand behind neurodegenerative diseases.

Authors:  Haoyang Lu; Xinzhou Liu; Yulin Deng; Hong Qing
Journal:  Front Aging Neurosci       Date:  2013-12-05       Impact factor: 5.750

Review 10.  Implications of DNA Methylation in Parkinson's Disease.

Authors:  Ernesto Miranda-Morales; Karin Meier; Ada Sandoval-Carrillo; José Salas-Pacheco; Paola Vázquez-Cárdenas; Oscar Arias-Carrión
Journal:  Front Mol Neurosci       Date:  2017-07-18       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.